Hikal logo

Hikal

HIKAL NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹2,767 Cr
Volatility
Moderate
P/E Ratio
-85.8
EBITDA
₹233 Cr
Return on Equity
-4.07%
Debt to Equity
0.57
Book Value
₹97.22
EPS
₹5.49
52W High
₹282.7
52W Low
₹146.25

Tapetide Score

Data-driven rating, 0–100. How it works →

Key Insights

Weaknesses

4
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -0.09% over past five years.
  • Company has a low return on equity of 5.16% over last 3 years.
  • Dividend payout has been low at 8.37% of profits over last 3 years

Growth Rate

Revenue Growth
-7.5% lower than 3Y
Net Income Growth
-154% lower than 3Y
Cash Flow Change
7.7% lower than 3Y
ROE
-157% lower than 3Y
ROCE
-108% higher than 3Y
EBITDA Margin (Avg.)
-24.55% lower than 3Y

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
388
435
448
514
407
453
448
552
380
319
494
519
403
Expenses
338
377
383
420
349
378
376
429
355
311
412
414
366
Operating Profit
50.3
57.52
64.7
94.4
58
74.9
72.1
123
25.1
7.2
82.7
105
37
OPM %
12.96%
13.23%
14.46%
18.36%
14.26%
16.54%
16.1%
22.34%
6.6%
2.26%
16.73%
20.29%
9.19%
Other Income
0.9
0.99
0.1
0.5
0.5
0.4
3.6
0.5
1
1.9
-35.2
-40.5
10.7
Interest
13.8
13.08
14.2
15.3
19.8
18.8
18.7
17.9
17.1
14.9
15.5
14.6
14.9
Depreciation
27.7
28.57
29
32.3
31.8
31.7
33.2
37.7
39.4
41.2
41.2
42
42.7
PBT
9.7
16.86
21.6
47.3
6.9
24.8
23.8
68.3
-30.4
-47
-9.2
8.3
-9.9
Tax %
28.87%
25.44%
25.46%
28.33%
26.09%
26.21%
27.73%
26.5%
-26.32%
-25.74%
-35.87%
-73.49%
-25.25%
Net Profit
6.9
12.57
16.1
33.9
5.1
18.3
17.2
50.2
-22.4
-34.9
-5.9
14.4
-7.4
EPS in Rs
0.56
1.02
1.31
2.75
0.41
1.48
1.39
4.07
-1.82
-2.83
-0.48
1.17
-0.6
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
872
926
1,014
1,296
1,590
1,507
1,720
1,943
2,023
1,785
1,860
1,713
1,735
Expenses
689
745
813
1,054
1,291
1,234
1,398
1,602
1,765
1,518
1,531
1,492
1,503
Operating Profit
182
181
201
242
298
273
323
341
258
267
328
220
232
OPM %
21%
20%
20%
19%
19%
18%
19%
18%
13%
15%
18%
13%
13%
Other Income
2
2
-3
4
2
-12
5
5
5
2
5
-73
-63
Interest
60
62
48
49
58
52
36
31
48
56
75
62
60
Depreciation
64
67
69
86
93
82
85
96
109
118
134
164
167
PBT
60
53
80
112
149
127
206
219
105
96
124
-78
-58
Tax %
32%
23%
16%
31%
31%
33%
36%
27%
26%
27%
27%
-38%
—
Net Profit
40
41
68
77
103
84
133
160
78
70
91
-49
-34
EPS in Rs
3.28
3.34
5.49
6.26
8.36
6.85
10.8
13.02
6.36
5.64
7.36
-3.96
-2.74
Div. Payout %
20%
20%
15%
13%
14%
18%
19%
12%
19%
21%
19%
-15%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
16
16
16
16
25
25
25
25
25
25
25
25
Reserves
516
547
589
653
732
792
909
1,043
1,109
1,163
1,238
1,174
Borrowings
547
505
598
635
661
646
610
675
748
818
765
684
Other Liabilities
212
206
177
237
268
306
370
470
504
482
502
483
Total Liabilities
1,292
1,275
1,379
1,542
1,686
1,768
1,913
2,213
2,385
2,487
2,529
2,365
Fixed Assets
639
623
668
634
713
735
713
879
948
1,071
1,364
1,333
CWIP
62
66
63
118
79
161
254
295
412
414
121
94
Investments
3
3
4
3
1
1
1
11
5
5
10
10
Other Assets
588
583
645
788
893
871
946
1,028
1,020
997
1,034
928
Total Assets
1,292
1,275
1,379
1,542
1,686
1,768
1,913
2,213
2,385
2,487
2,529
2,365
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
102
186
163
139
186
285
229
294
315
187
280
302
Investing
-43
-64
-102
-110
-125
-164
-156
-284
-292
-174
-136
-145
Financing
-69
-124
-63
-25
-55
-101
-97
-6
-8
-27
-144
-160
Net Cash Flow
-10
-2
-2
4
6
20
-24
4
15
-14
0
-3
Free Cash Flow
54
127
58
33
57
127
71
21
13
-17
144
154
CFO/OP
63
110
91
68
73
113
85
107
134
81
94
144
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
54
44
92
81
80
82
103
82
80
113
103
94
Inventory Days
268
229
189
158
156
147
107
121
104
134
146
172
Days Payable
117
101
93
86
68
95
92
91
103
123
133
128
Cash Conversion Cycle
205
173
188
153
168
135
118
112
81
124
116
138
Working Capital Days
-13
29
43
29
45
28
39
26
39
39
37
41
ROCE %
11%
11%
12%
13%
15%
14%
16%
15%
8%
8%
10%
4%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Hikal insights

66 extracted metrics + investor summaries across FY06–FY27.

Log in — free

Shareholding Pattern

FIIs0.99%Promot.68.85%Others5.09%DIIs7.24%Public17.84%As ofJun 2026

Documents

Frequently Asked Questions about Hikal

What does Hikal Ltd do?
Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by le...
Where is Hikal Ltd (HIKAL) listed?
Hikal Ltd trades as HIKAL on the NSE and under code 524735 on the BSE.
Which sector does Hikal Ltd belong to?
Hikal Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Hikal Ltd?
Hikal Ltd has a market capitalisation of ₹2,767 Cr, which places it in the Small Cap band.
What is the PE ratio of Hikal Ltd?
Hikal Ltd trades at a PE ratio of -85.80, on earnings per share of ₹5.49, against a book value of ₹97.22 per share.
What is the 52-week high and low of Hikal Ltd?
Over the last 52 weeks Hikal Ltd has traded between ₹146.25 and ₹282.7.
Does Hikal Ltd pay dividends?
Hikal Ltd has a dividend yield of 0.26%.
What is the Return on Equity (ROE) of Hikal Ltd?
Hikal Ltd reported a return on equity of -4.07%. Its debt-to-equity ratio is 0.57.

Company Information

Hikal is a partner to companies in the Pharmaceuticals, Crop Protection, and Specialty Chemicals industry. The company is in the business of supplying research services, active ingredients and intermediates for its customers. Hikal's manufacturing facilities have been inspected and approved by leading multinational companies in the Crop protection and Pharmaceutical sectors. The Crop protection facilities are located at Taloja and Mahad {Maharashtra). The Pharmaceutical manufacturing facilities are situated in Jigani (Bengaluru) and Panoli (Gujarat). Hikal's R & D facilities are located in Pune.[1]

Website hikal.com
CEO Mr. Jai Vishwanath Hiremath
Employees 2,062
Listed 2001-02-14
Face Value ₹ 2
Issued Size 12,33,00,750

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/HIKAL.md for Hikal Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our MCP server.

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List